- FibroBiologics to Present at the BIO International Convention 2024
- FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
- FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
- FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
- FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
More ▼
Key statistics
On Tuesday, Fibrobiologics Inc (FBLG:NMQ) closed at 9.22, 41.19% above the 52 week low of 6.53 set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.75 |
---|---|
High | 9.46 |
Low | 8.00 |
Bid | 9.20 |
Offer | 9.55 |
Previous close | 8.74 |
Average volume | 57.83k |
---|---|
Shares outstanding | 32.72m |
Free float | 22.79m |
P/E (TTM) | -- |
Market cap | 285.97m USD |
EPS (TTM) | -0.9149 USD |
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.
More ▼